SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    American Cancer Society. Breast Cancer Facts & Figures. Atlanta, GA: American Cancer Society; 2012.
  • 2
    Lash TL, Silliman RA. Re: prevalence of cancer. J Natl Cancer Inst. 1998; 90: 399-400.
  • 3
    Reis L, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2005. In: Edwards BK, ed. Bethesda, MD: National Cancer Institute; 2008. Available at: http://seer.cancer.gov/csr/1975_2005/. [Accessed June 15, 2012.]
  • 4
    Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist. 2007; 12: 20-37.
  • 5
    Mariotto AB, Rowland JH, Ries LA, Scoppa S, Feuer EJ. Multiple cancer prevalence: a growing challenge in long-term survivorship. Cancer Epidemiol Biomarkers Prev. 2007; 16: 566-571.
  • 6
    Travis LB. Therapy-associated solid tumors. Acta Oncol. 2002; 41: 323-333.
  • 7
    Travis LB, Rabkin CS, Brown LM, et al. Cancer survivorship—genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst. 2006; 98: 15-25.
  • 8
    Boice JDJr, Harvey EB, Blettner M, Stovall M, Flannery JT. Cancer in the contralateral breast after radiotherapy for breast cancer. N Engl J Med. 1992; 326: 781-785.
  • 9
    Gotay CC, Ransom S, Pagano IS. Quality of life in survivors of multiple primary cancers compared with cancer survivor controls. Cancer. 2007; 110: 2101-2109.
  • 10
    Hemminki K, Ji J, Forsti A. Risks for familial and contralateral breast cancer interact multiplicatively and cause a high risk. Cancer Res. 2007; 67: 868-870.
  • 11
    Kirova YM, Gambotti L, De Rycke Y, Vilcoq JR, Asselain B, Fourquet A. Risk of second malignancies after adjuvant radiotherapy for breast cancer: a large-scale, single-institution review. Int J Radiat Oncol Biol Phys. 2007; 68: 359-363.
  • 12
    Ng AK, Travis LB. Second primary cancers: an overview. Hematol Oncol Clin North Am. 2008; 22: 271-289, vii.
  • 13
    Storm HH, Andersson M, Boice JDJr, et al. Adjuvant radiotherapy and risk of contralateral breast cancer. J Natl Cancer Inst. 1992; 84: 1245-1250.
  • 14
    Avila CC, Quinn VP, Geiger AM, Kerby TJ, St Charles M, Clough-Gorr KM. Webinar training: an acceptable, feasible and effective approach for multi-site medical record abstraction: the BOWII experience [serial online]. BMC Res Notes. 2011; 4: 430.
  • 15
    National Cancer Institute; Surveillance, Epidemiology, and End Results (SEER) Program. SEER Program Coding and Staging Manual, 2007. In: Johnson CH, Adamo M, eds. Bethesda, MD: National Cancer Institute; 2007. Available at: http://seer.cancer.gov/manuals/2007/SPCSM_07_maindoc.pdf. [Accessed June 15, 2012.]
  • 16
    Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373-383.
  • 17
    Rosthoj S, Andersen PK, Abildstrom SZ. SAS macros for estimation of the cumulative incidence functions based on a Cox regression model for competing risks survival data. Comput Methods Programs Biomed. 2004; 74: 69-75.
  • 18
    Pintilie M. Competing Risks: A Practical Perspective. West Sussex, United Kingdom: John Wiley & Sons, Ltd.; 2006.
  • 19
    Greenland S. Chapter 21. Introduction to regression modeling. In: Rothman KJ, Greenland S, Lash TL, eds. Modern Epidemiology.3rd ed. Philadelphia, PA: Lippincott-Raven; 1998: 401-434.
  • 20
    SAS Institute, Inc. Statistical Analysis System (SAS) version 9.2 [software package]. Cary, NC: SAS Institute, Inc.; 2006.
  • 21
    American Cancer Society. Breast Cancer Facts & Figures. Atlanta, GA: American Cancer Society; 2010.
  • 22
    Brown LM, Chen BE, Pfeiffer RM, et al. Risk of second non-hematological malignancies among 376,825 breast cancer survivors. Breast Cancer Res Treat. 2007; 106: 439-451.
  • 23
    Curtis RE, Freedman DM, Ron E, et al, eds. New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000. Bethesda, MD: National Cancer Institute; 2006.
  • 24
    Schoen RE, Weissfeld JL, Kuller LH. Are women with breast, endometrial, or ovarian cancer at increased risk for colorectal cancer? Am J Gastroenterol. 1994; 89: 835-842.
  • 25
    Newschaffer CJ, Topham A, Herzberg T, Weiner S, Weinberg DS. Risk of colorectal cancer after breast cancer. Lancet. 2001; 357: 837-840.
  • 26
    Eisen GM, Sandler RS. Are women with breast cancer more likely to develop colorectal cancer? Critical review and meta-analysis. J Clin Gastroenterol. 1994; 19: 57-63.
  • 27
    Srinivasan R, Yang YX, Rubin SC, Morgan MA, Lewis JD. Women with a prior diagnosis of breast cancer are not at an increased risk for subsequent colorectal cancer. Am J Gastroenterol. 2005; 100: 2759-2764.
    Direct Link:
  • 28
    Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornander T, Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. J Natl Cancer Inst. 1995; 87: 645-651.